



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Vivitrol™

Common Name: Naltrexone HCl Injection

PDL Category: Narcotic - Antagonists

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Naltrexone HCl Tab	Preferred
ReVia®	Non-Preferred

Summary

Indications and Usage: Treatment of alcohol dependence

Dosage Forms: Injection, 380 mg powder for suspension (extended-release microspheres)

Recommended Dosage: 380mg IM once every four weeks

Common Adverse Drug Reactions: Nausea, headache, vomiting, dizziness

Contraindications: Concurrent use of opioid therapy, hypersensitivity to naltrexone, acute hepatitis, hepatic dysfunction

Manufacturer: Alkermes, Inc. and Cephalon, Inc.

Analysis: Vivitrol™ is the first and only FDA approved extended-release injection available for alcohol dependence. Patients using Vivitrol™ need to abstain from drinking and should combine drug therapy with psychosocial support. Vivitrol™ is injected intramuscularly once-a-month and is gradually released at a controlled rate reducing the concern for patient compliance with daily oral medications. Vivitrol™ has not been compared in head-to-head studies with oral naltrexone to support the assertion that the depot formulation of Vivitrol™ will improve compliance and efficacy. Other drugs on the PDL used to treat alcohol dependence within this drug class, in addition to Antabuse®, have preferred status and are more cost effective.

IME Recommendation:

Preferred Drug

Recommended Drug

Non-Preferred Drug

Non-Recommended Drug

Preferred Drug with Conditions